Docket: PP1627.003

1632 to

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

John James Donnelly et al.

Application No.: Date Filed:

09/715,902 11/17/2000

Title:

MICROPARTICLE-BASED TRANSFECTION AND ACTIVATION OF

**DENDRITIC CELLS** 

Group Art Unit:

1632

Examiner:

Anne Maria Sabrina Wehbé

Atty. Docket No.:

PP1627.003

## INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIR:

In accordance with 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §§1.97 and 1.98, the references listed on attached Form PTO/SB/08 and/or subsequently identified herein, are being submitted herewith for consideration by the United States Patent and Trademark Office

	1 101 0011	nderation by the children	nes i atent and i rademark office.	
I.	COPIES	3	•	
	a. 🖾		n U.S. and foreign patents; (ii) eac d; and (iii) all other information or rewith.	
	b.	not enclosed herewith we	or other information which are list are previously cited by or submitted hich has been relied upon for an	ed to the PTO in one of the
		U.S. Serial Number		U.S. Filing Date
II.	CONCI	SE EXPLANATION OF T	HE RELEVANCE (check at least o	one box)
	a. 🛛	Except as may be indicate	ed below in (b) of this section, all one English language (concise explan	f the patents, publications or
	b. 🗌	A concise explanation of	the relevance of all patents, publication language is as follows:	
	c. 🗌		nformation is provided for the Exam	miner's consideration:
III. 🗌	The Ext	y be related to the prese	FED APPLICATION(S)  following co-pending application nt application. By bringing this does(do) not waive the confidentia	(these) applications to the
	Serial N	<u>o.</u>	Filing Date	Art Unit

07/09/2004 DEMMANU1 00000084 501047 09715902

01 FC:1806

180.00 DA

Docket: PP1627.003

## **FEES**

IV. 🗌	THIS II	OS IS BEING FILED UNDER 37 C.F.R. §1.97(b): (check one box) within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d) (37 C.F.R. §1.97(b)(1)). No fee or statement is required.
	b c d	within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. §1.97(b)(2)). No fee or statement is required. before the mailing date of a first Office Action on the merits (37 C.F.R. §1.97(b)(3)). No fee or statement is required. before the mailing date of a first Office Action after the filing of a request for continued examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
V. 🛛	before t	OS IS BEING FILED UNDER 37 C.F.R. §1.97(c): (check one box) the mailing date of any of a Final Office Action under 37 C.F.R. §1.113, a Notice of once under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the ion (See 37 C.F.R. §1.97(c)).  No statement; therefore, charge deposit account 50-1047 the fee set forth in 37 C.F.R. §1.17(p).  See the statement below. No fee is required.
VI. 🗌		OS IS BEING FILED UNDER 37 C.F.R. §1.97(d): fore payment of the issue fee and is accompanied by the following: a statement under 37 C.F.R. §1.97(e) as provided below; and charge deposit account 50-1047 the petition fee set forth in §1.17(p).
VII. 🗆		dersigned hereby states that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of IDS; or no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and to knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the IDS was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement, or some of the items of information contained in the IDS were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the IDS was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.
VIII.	PAYMI	A check in the amount of is enclosed for the above-identified fee(s).  Please charge Deposit Account No. 50-1047 in the amount of \$180.00 for the above-indicated fee(s).  If Applicant has overlooked any additional fees, or if any overpayment has been made, the Commissioner is hereby authorized to credit or debit Deposit Account 50-1047.  Two Copies of this paper are attached for Deposit Account charges and debits.

Docket: PP1627.003

It is Applicant(s)' opinion that the claims presently on file patently distinguish the present invention from each of these references. The above references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in a combination, to a person of ordinary skill in the art.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 50-1047.

Keum J. Park Attorney for Applicant(s) Reg. No. 42,059 Tel. 908-518-7700 Fax: 908-517-7798

Respectfully submitted,

MAYER FORTKORT & WILLIAMS Customer Number 27774

**Enclosures:** 

☐ Foreign Search Report
☐ Other:

PTO/SB/08 References

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited

7/2/6 4 with the U.S. Postal Service as first class mail

under 37 C.F.R. 1.8 and is addressed to Mail Stop DD, Commissioner for Patents,

P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Joanne Ryan

Typed or Printed Name of Person Mailing Certificate

OIP Docket No.: PP1627.003

Pleasetype a plus sign (+) inside this box. FORM PTO/SB/08

EMARITA Substitute	for form 1449A/PTO			Complete if Known			
	<b></b>			Application Number	09/715,902		
	MATION DISCLO			Filing Date	11/17/2000		
STATE	MENT BY APPLI	CANT		First Named Inventor	John James Donnelly et al.		
				Group Art Unit	1632		
	ny sheets as necessary)			Examiner Name	Anne Maria Sabrina Wehbé		
Sheet	1	of	2	Attorney Docket Number	1627.003		

Examiner	Cite	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of Cited Document MM-	
Initials*	No. 1	Number	Class/Subclass	of Cited Document	DD-YYYY	
	-				7	
		<del></del>				
	<del> </del>	<del> </del>		_		
	<del> </del>					
	<b>!</b>	<b>-</b>				
	<u> </u>					
		<u> </u>				
	,	<u> </u>	<del></del>			
	t		· · · · · · · · · · · · · · · · · · ·			
	<del>                                     </del>	<del>                                     </del>				
	<b></b>					
	-	<del></del>				
	<u> </u>					

Examiner	Cite		Foreign Patent	Document	Name of Patentee or Applicant of	Date of Publication of Cited	T
Initials*	No.	Office <sup>3</sup>	Number ⁴	Class/Subclass	Cited Document	Document MM-DD-YYYY	
	1.	WO	97/02810	A61K 9/16	University of Nottingham	01/30/1997	
		-		<u>.                                      </u>			
		1			<del> </del>		
							<del></del>
			*	7			
	L	<u></u>					

	· · · · · · · · · · · · · · · · · · ·		
Examiner		Date	
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

pcket No.: PP1627.003

TRATELEDEE type a plus sign (+) inside this box. FORM PTO/SB/08

Substitute for	or form 1449A/PTO			Complete if Known		
				Application Number	09/715,902	
INFORM	1ATION DISC	LOSURE		Filing Date	11/17/2000	
STATEMENT BY APPLICANT				First Named Inventor	John James Donnelly et al.	
				Group Art Unit	1632	
(use as many	sheets as necessar,	<u>v)</u>		Examiner Name	Anne Maria Sabrina Wehbé	
Sheet	2	of	2	Attorney Docket Number	PP1627.003	

<del></del>		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	T <sup>2</sup>						
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	1.	ANDREAS LUNDQVIST ET AL., "Nonviral and Viral Gene Transfer into Different Subsets of Human Dendritic Cells Yield Comparable Efficiency of Transfection," <i>Journal of Immunology</i> , Vol. 25, no. 6, 2002, pp. 445-454.							
	2.	D.T. O'HAGAN et al., "Long-Term Antibody Responses in Mice Following Subcutaneous Immunization with Ovalbumin Entrapped in Biodegradable Microparticles," Vaccine, Vol. 11, no. 9, 1993, pp. 965-969.							
<del></del>	3.	AWASTHI S. COX. Abstract of "Transfection of Murine Dendritic Cell Line (JAWS II) by a Nonviral Transfection Reagent," <i>Biotechniques</i> , Vol. 35, no. 3, 2003, pp. 600-602, 604.							
-	4.	SHUICHI ANDO et al, "PLGA Microspheres Containing Plasmid DNA: Preservation of Supercoiled DNA via Cryopreparation and Carbohydrate Stabilization," <i>Journal of Pharmaceutical Sciences</i> , Vol. 88, no. 1, 1999, pp. 126-130							
	5.	ELKE WALTER et al., "Microencapsulation of DNA Using Poly (DL-lactide-co-glycolide): Stability Issues and Release Characteristics," <i>Journal of Controlled Release</i> , Vol. 61, 1999, pp. 361-374.							
	6.	SHIBAGAKI N. UDEY, Abstract of "Dendritic Cells Transduced with Protein Antigens Induce Cytotoxic Lymphocytes and Elicit Antitumor Immunity," <i>Journal of Immunology</i> , Vol. 168, no. 5, 2002, pp. 2393-2401.							
	7.	P. LENZ et al., Abstract of "Nucleoporation of Dendritic Cells: Efficient Gene Transfer by Electroporation into Human Monocyte-Derived Dendritic Cells," <i>FEBS Lett.</i> , Vol. 538, no. 1-3, 2003, pp. 149-154.							
	8.	TAKASHIMA A. MORITA, Abstract of "Dendritic Cells in Genetic Immunization," Journal of Leukocyte Biology, Vol. 66, no. 2, 1999, pp. 350-356.							
	9.	L. ZHONG et al., Abstract of "Recombinant Adenovirus Is an Efficient and Non-Perturbing Genetic Vector for Human Dendritic Cells," Eur. J. Immunol., Vol. 29, no. 3, 1999, pp. 964-972.							

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. Applicant is to place a check mark here if English Language Translation is attached.